Tag: Olaparib

Long-term benefit of olaparib seen in high-risk early BRCA1/2-mutated breast cancer

Presented By
Prof. Judy Garber, Dana-Farber Cancer Institute, MA, USA
Trial
Phase 3, OlympiA
Conference
SABCS 2024
Type
Peer-reviewed article

23 January 2025 16:31

Olaparib maintenance has favourable safety profile in TNBC

Presented By
Prof. Hope Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, CA, USA
Trial
Phase 2, KEYLYNK-009
Conference
SABCS 2023
Type
News article

11 January 2024 14:57

Immune checkpoint inhibition improves PFS in non-BRCA-mutated ovarian cancer

Presented By
Dr Philipp Harter, Kliniken Essen-Mitte, Germany
Trial
Phase 3, DUO-O
Conference
ASCO 2023
Type
Peer-reviewed article

1 August 2023 12:44

OS benefit for advanced ovarian cancer patients treated with maintenance olaparib

Presented By
Prof. Isabelle Ray-Coquard, Centre Léon Bérard, France
Trial
Phase 3, PAOLA-1/ENGOT-ov25
Conference
ESMO 2022
Type
Peer-reviewed article

17 November 2022 00:57

PROpel: Good results for abiraterone plus olaparib in mCRPC

Presented By
Prof. Noel Clarke, University of Manchester, UK
Trial
Phase 3, PROpel
Conference
EAU 2022
Type
News article

22 July 2022 12:37

First-line treatment with olaparib significantly improves PFS in mCRPC

Presented By
Dr Fred Saad, Centre Hospitalier de l’Université de Montréal, Canada
Trial
Phase 3, PROpel
Conference
ASCO GU 2022
Type
Peer-reviewed article

8 April 2022 11:25

No benefit of olaparib in previously untreated, platinum-ineligible, metastatic urothelial carcinoma

Presented By
Dr Jonathan Rosenberg, Memorial Sloan Kettering Cancer Center, NY, USA
Trial
Phase 2, BAYOU
Conference
ASCO GU 2022
Type
Peer-reviewed article

8 April 2022 11:19

Olaparib is well tolerated as an additional treatment

Presented By
Dr Patricia Ganz, UCLA School of Medicine, CA, USA
Trial
Phase 3, OlympiA
Conference
SABCS 2021
Type
Peer-reviewed article

31 January 2022 22:26

SABCS 2021 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom
Conference
SABCS 2021

10 January 2022 20:59

PARP inhibitor rechallenge improves PFS in ovarian cancer

Presented By
Dr Eric Pujade-Lauraine, Université Paris Descartes, France
Trial
Phase 3, OReO/ENGOT Ov-38
Conference
ESMO 2021
Type
Peer-reviewed article

19 November 2021 09:24

HRR mutational status is prognostic and predictive biomarker olaparib activity

Presented By
Dr Joyce Liu, Dana-Farber Cancer Institute, MA, USA
Trial
Phase 3, NRG-GY004
Conference
ESMO 2021
Type
Peer-reviewed article

19 November 2021 09:20

Olaparib benefits early breast cancer patients with BRCA1/2 germline mutation

Presented By
Prof. Andrew Tutt , Institute of Cancer Research, UK
Trial
OlympiA
Conference
ASCO 2021
Type
Peer-reviewed article

12 August 2021 22:47

The EFFORT needed to overcome PARP resistance in ovarian cancer

Presented By
Dr. Shannon Neville Westin, University of Texas, MD Anderson Center
Trial
Phase 2, EFFORT
Journal
Physician's Weekly
Conference
ASCO 2021

6 August 2021 12:40

Adjuvant olaparib extends disease-free survival in BRCA carriers

Presented By
Dr. Judy Ellen Garber, Dana-Farber Cancer Institute, Harvard Medical School
Trial
OlympiA
Journal
Physician's Weekly
Conference
ASCO 2021

6 August 2021 12:30

No survival benefit for olaparib in BRCA-mutated metastatic pancreatic cancer

Presented By
Prof. Talia Golan, Sheba Medical Center, Israel
Trial
Phase 3, POLO
Conference
ASCO GI 2021
Type
Peer-reviewed article

12 March 2021 11:02

New treatment option for patients with mCRPC

Conference
ESMO 2020
Type
Peer-reviewed article

25 November 2020 14:50

Treatment of newly diagnosed ovarian cancer

Conference
ESMO 2020
Type
Peer-reviewed article

25 November 2020 14:39

Maintenance olaparib improves OS in relapsed ovarian cancer with BRCA1/2 mutation

Presented By
Prof. Andrés Poveda, Hospital Quironsalud, Spain
Trial
Phase 3, SOLO2/ENGOT-ov21
Conference
ASCO 2020

8 September 2020 09:35

Ovarian cancer patients benefit from combined maintenance therapy

Presented By
Prof. Isabelle Ray-Coquard, Université Claude Bernard, Lyon, France
Trial
Phase 3, PAOLA-1/ENGOT-ov25
Conference
ESMO 2019
Type
Peer-reviewed article

26 November 2019 23:25

PARP inhibition in selected patients slows progression on advanced prostate cancer

Presented By
Prof. Maha Hussain, Northwestern University, Chicago, USA
Trial
Phase 3, PROfound
Conference
ESMO 2019
Type
Peer-reviewed article

26 November 2019 21:24

Maintenance olaparib improved PFS in patients with BRCA+ pancreatic cancer

Presented By
Dr Hedy L. Kindler, The University of Chicago, USA
Trial
Phase 3, POLO
Conference
ASCO 2019
Type
Peer-reviewed article

15 July 2019 14:07
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com